Overall rank by patents
#44,613
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2018–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B01D (SEPARATION).
The verdict
Arstroma holds 5 US patents across 5 technology areas, rank #44,613 of 50,000 tracked assignees.
Arstroma Co., Ltd. has been granted 5 US utility patents between 2018 and 2022, placing Arstroma Co., Ltd. at rank #44,613 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.6 claims per patent with primary concentration in B01D (SEPARATION). As a Foreign Corporation, Arstroma Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Arstroma sits between ARO Biotherapeutics Company (5 patents, rank #44,609) and ARUP Ventures Limited (5 patents, rank #44,617) - the closest US assignees by grant volume. The composite Innovation Score of 23.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 1 in the 2015–2019 window, a +300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Arstroma Co., Ltd.'s 12.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Arstroma Co., Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ARO Biotherapeutics Company
5 patents
AROBOTECH SYSTEMS, INC.
5 patents
ARRIS Global Ltd.
5 patents
ARS ELECTRONICA LINZ GMBH & CO. KG
5 patents
ARTERIAL REMODELING TECHNOLOGIES SA
5 patents
ARTHROSI THERAPEUTICS, INC.
5 patents
ARTS
5 patents
ARUP VENTURES LIMITED
5 patents
ARSTROMA CO., LTD.
5 patents
What this shows Arstroma holds 5 patents at rank #44,613, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #44,613 in granted patent volume.
Other assignees with the most granted patents in Arstroma's primary technology class.
Arstroma's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
24 Top 87% higher than 13% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 20.0% |
| 2020 | 1 | 20.0% |
| 2021 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
Top 5 of 5 technology areas
Overall rank by patents
#44,613
Across all tracked assignees
23.9 out of 100
How to use this portfolio
Arstroma's 5 grants land it in the top 87% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.